Chen et al., (2016), found that ANXA4 is significantly elevated in HCC patients with early recurrence, and had a strong correlation with portal vein tumor thrombosis (p = 0.03) and advanced BCLC stage (p = 0.002) and might act as a potential prognostic biomarker for HCC. Here, ANXA4 is linked to hepatocellular carcinoma.